Oneness Biotech Co

Oneness Biotech Co EBIT per Share

The EBIT per Share of Oneness Biotech Co (4743.TWO) as of Oct 31, 2026 is -1.67 TWD. In the previous year, EBIT per Share was -2.16 TWD — a change of -22.88% (higher).

EBIT per Share

-1.67TWD

YoY

-22.88%

Last updated:

EBIT per Share of Oneness Biotech Co is 2025 -1.67 TWD. EBIT per Share of Oneness Biotech Co was 2024 -2.16 TWD. It decreases by -22.88% higher compared to the previous year.

The Oneness Biotech Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2020
-0.65 TWD
Jan 1, 2021
-1.02 TWD
Jan 1, 2022
1.03 TWD
Jan 1, 2023
-2.30 TWD
Jan 1, 2024
-2.16 TWD
Jan 1, 2025
-1.67 TWD
Jan 1, 2026 (e)
0.00 TWD
Jan 1, 2027 (e)
-1.24 TWD
The Oneness Biotech Co EBIT per Share history
YEAREBIT per ShareYoY
est-1.24TWD—
est0.00TWD-100.00%
-1.67TWD-22.88%
-2.16TWD-6.11%
-2.30TWD-324.03%
1.03TWD-200.48%
-1.02TWD+57.79%
-0.65TWD-46.37%
-1.21TWD-3.92%
-1.26TWD+55.19%
-0.81TWD+41.03%
-0.57TWD+10.03%
-0.52TWD-24.28%
-0.69TWD-4.76%
-0.72TWD+51.26%
-0.48TWD+5.13%
-0.46TWD+180.57%
-0.16TWD-42.32%
-0.28TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oneness Biotech Co Stock analysis

What does Oneness Biotech Co do? Oneness Biotech Co., Ltd. generates revenue through the research and development of new drugs and the sale of pharmaceutical products and health products. The company focuses on health supplies, health food, and healthy food as its main products, which are distributed domestically. It also develops new drugs for treating chronic diabetic foot ulcers and anticancer drugs, targeting the domestic market for both its existing and new product lines. The firm's primary customers are domestic consumers seeking health and pharmaceutical solutions, including those requiring wound healing treatments for diabetic foot ulcers and anticancer therapies. Its product portfolio includes health supplies, health food, healthy food, and specialized drug developments, all sold within Taiwan's domestic market. Oneness Biotech's business model centers on developing and selling health and pharmaceutical products, with a particular emphasis on niche medical applications like diabetic foot ulcer treatments and cancer drugs. The company leverages its domestic distribution network to reach consumers interested in health-focused solutions and specialized medical treatments. Oneness Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oneness Biotech Co stock

EBIT per Share of Oneness Biotech Co is -1.67 TWD in 2025.

EBIT per Share of Oneness Biotech Co changed from -2.16 TWD to -1.67 TWD, representing a -22.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Oneness Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Oneness Biotech Co

All Key Metrics — Oneness Biotech Co